GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Piotroski F-Score

Walvax Biotechnology Co (SZSE:300142) Piotroski F-Score : 4 (As of May. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Walvax Biotechnology Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Walvax Biotechnology Co's Piotroski F-Score or its related term are showing as below:

SZSE:300142' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Walvax Biotechnology Co was 7. The lowest was 3. And the median was 5.


Walvax Biotechnology Co Piotroski F-Score Historical Data

The historical data trend for Walvax Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Piotroski F-Score Chart

Walvax Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 5.00 6.00 5.00

Walvax Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 5.00 5.00 4.00

Competitive Comparison of Walvax Biotechnology Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 283.249 + 98.137 + -133.986 + 14.128 = ¥262 Mil.
Cash Flow from Operations was 182.467 + 475.269 + 272.832 + -75.593 = ¥855 Mil.
Revenue was 1334.404 + 990.373 + 955.728 + 599.754 = ¥3,880 Mil.
Gross Profit was 1186.684 + 811.676 + 809.435 + 486.235 = ¥3,294 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(15434.647 + 15650.334 + 15591.154 + 15588.869 + 15386.882) / 5 = ¥15530.3772 Mil.
Total Assets at the begining of this year (Mar23) was ¥15,435 Mil.
Long-Term Debt & Capital Lease Obligation was ¥448 Mil.
Total Current Assets was ¥8,496 Mil.
Total Current Liabilities was ¥2,978 Mil.
Net Income was 382.389 + 110.384 + 197.259 + 171.991 = ¥862 Mil.

Revenue was 1692.154 + 1358.215 + 1380.187 + 833.267 = ¥5,264 Mil.
Gross Profit was 1475.281 + 1216.651 + 1205.112 + 708.42 = ¥4,605 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(14008.442 + 14978.623 + 14843.448 + 15336.026 + 15434.647) / 5 = ¥14920.2372 Mil.
Total Assets at the begining of last year (Mar22) was ¥14,008 Mil.
Long-Term Debt & Capital Lease Obligation was ¥390 Mil.
Total Current Assets was ¥8,875 Mil.
Total Current Liabilities was ¥3,337 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Walvax Biotechnology Co's current Net Income (TTM) was 262. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Walvax Biotechnology Co's current Cash Flow from Operations (TTM) was 855. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=261.528/15434.647
=0.01694422

ROA (Last Year)=Net Income/Total Assets (Mar22)
=862.023/14008.442
=0.06153597

Walvax Biotechnology Co's return on assets of this year was 0.01694422. Walvax Biotechnology Co's return on assets of last year was 0.06153597. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Walvax Biotechnology Co's current Net Income (TTM) was 262. Walvax Biotechnology Co's current Cash Flow from Operations (TTM) was 855. ==> 855 > 262 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=448.255/15530.3772
=0.02886311

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=390.1/14920.2372
=0.0261457

Walvax Biotechnology Co's gearing of this year was 0.02886311. Walvax Biotechnology Co's gearing of last year was 0.0261457. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=8496.107/2977.683
=2.85326108

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=8875.468/3337.105
=2.65963103

Walvax Biotechnology Co's current ratio of this year was 2.85326108. Walvax Biotechnology Co's current ratio of last year was 2.65963103. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Walvax Biotechnology Co's number of shares in issue this year was 1605.402. Walvax Biotechnology Co's number of shares in issue last year was 1601.405. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3294.03/3880.259
=0.84892014

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4605.464/5263.823
=0.8749276

Walvax Biotechnology Co's gross margin of this year was 0.84892014. Walvax Biotechnology Co's gross margin of last year was 0.8749276. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=3880.259/15434.647
=0.25139927

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=5263.823/14008.442
=0.37576077

Walvax Biotechnology Co's asset turnover of this year was 0.25139927. Walvax Biotechnology Co's asset turnover of last year was 0.37576077. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Walvax Biotechnology Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Walvax Biotechnology Co  (SZSE:300142) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Walvax Biotechnology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co (SZSE:300142) Business Description

Traded in Other Exchanges
N/A
Address
Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines